The Clinical Utility of Serum YKL-40 Levels in Community Acquired Pneumonia

Halit Cınarka, Aziz Gumus, Mevlut Karatas, Servet Kayhan, Aynur Kırbas, Songul Ozyurt, Aysel Kurt, Unal Sahin

Abstract


Introduction: We aimed to investigate the changes in blood levels of YKL-40 in patients hospitalized with a diagnosis of community acquired pneumonia (CAP) before treatment and on the 7th day of treatment and to determine whether this can be used as a diagnostic and prognostic marker in the disease.

 

Methodology: Sixty-two subjects including 40 with CAP and 22 healthy as a control group were enrolled to the study. Serum YKL-40 levels were measured in patients with CAP before treatment and on the seventh day of the treatment. Degrees of severity of pneumonia were evaluated according to CURB-65 and the Pneumonia Severity Index (PSI).

 

Results: Mean serum YKL-40 levels of 89.24±98.67 ng/ml and 74.37±56.28 ng/ml were measured on the 1st and 7th days, respectively. The difference between two measurements was significant (p=0.003). A significant difference was also determined in serum YKL-40 level between control group and patient with CAP group on 1st and 7th days (p=0.001 and p<0.001, respectively). PSI and CURB-65 scores were not correlated with serum YKL-40 levels in patients with CAP.

 

Conclusion: The results show higher blood YKL-40 levels in patients in the CAP group compared to the controls. Elevated YKL-40 levels in blood specimens at the start of treatment in our pneumonia group, followed by a decrease one week later, may be regarded as evidence that blood YKL-40 levels can be used as an inflammation marker in clinical practice.

 

Keywords: Pneumonia; YKL-40; C-reactive protein


Full Text:

PDF

References


Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:761–776.

Waterer GW, Rello J, Wundernk RG. Management of community-acquired pneumonia in adults: concise clinical review. Am J Respir Crit Care Med 2011; 183: 157-64.

Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis. 1999;180(5):1722-6.

M.S. Niederman, L.A. Mandell, A. Anzueto et al. “Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention“ Am J Respir Crit Care Med, 2001:163,1730–54.

Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance,1995–1997. Am J Public Health 2000; 90:223–9.

Özlü T, Bülbül Y, Alataş F, Arseven O, Coşkun AŞ, Çilli A, et al. Turkish Thoracic Society Community-Acquired Pneumonia Guideline. Turk Toraks Derg 2009.

Torres A, Ramirez P, Montull B, Menéndez R. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med. 2012;33(3):266-71

Wang HL, Hsiao PC, Tsai HT, Yeh CB, Yang SF. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients. Int J Mol Sci. 2013;14(11):22817-25.

Rathcke, C.N. & Vestergaard, H. YKL-40 — an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc. Diabetol., 2009: 8, 61.

Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53(2):172-209.

Kushner I.The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:38-48.

Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10.

Renkema, G.H., Boot, R.G., Au, F.L., Donker-Koopman, W.E., Strijland, A., Muijsers, A.O., Hrebicek, M. & Aerts, J.M. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macro-phages. Eur. J. Biochem., 1998: 251, 504-509.

Chitinaz and lung disease. Serap Duru,Melike Yüceege, Sadık Ardıç. Tuberk Toraks 2013;61(1),71-75.

Cheng CW, Chien MH, Su SC, Yang SF. New markers in pneumonia. Clin Chim Acta. 2013;419:19-25.

.Kzhshkowska J, Gratcev A, Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomarker Insights 2007; 2: 128-46.

Funkhouser JD, Aronson NN Jr. Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family. BMC Evol Biol 2007;7:96.

Kronborg, G.; Ostergaard, C.; Weis, N.; Nielsen, H.; Obel, N.; Pedersen, S.S.; Price, P.A.; Johansen, J.S. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand. J. Infect. Dis. 2002, 34, 323–326.

Letuve S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol. 2008;181(7):5167-73.

Kayhan S, Gumus A, Cinarka H, Murat N, Yilmaz A, Bedir R, Sahin U. The clinical utility of pleural YKL-40 levels in diagnosing pleural effusions. J Thorac Dis. 2013;5(5):634-40.


Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2019 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine